Biologic Therapies for Severe Asthma: Current Insights and Future Directions
Journal of Clinical Medicine · 02.05.2025 · 14 (9) · 3153
DOI: 10.3390/jcm14093153 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.05.2025. Verfasst von Nuno Faria und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department, Unidade Local de Saúde de Santo António, 4099-001 Porto, Portugal. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe asthma is a subset of difficult-to-treat asthma that requires the verification of inhaler technique, the correction of modifiable risk factors, as well as diagnosis and comorbidity review. When severe asthma is suspected, patients should undergo proper phenotyping (T2-high or T2-low) and be referred to a specialized severe asthma clinic. The current biologics for severe asthma treatment include omalizumab (anti-IgE), mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor), dupilumab (anti-IL-4/IL-13), and tezepelumab (anti-TSLP). The outcomes to evaluate are the reduction in systemic corticosteroid use, the reduction in exacerbations and healthcare use, and improvement in symptoms and lung function. Comorbidities should be carefully considered, and if possible, addressed with the same biologic. Dupilumab, mepolizumab, and omalizumab are also approved for chronic rhinosinusitis with nasal polyps (CRSwNP), the most common asthma comorbidity. There are currently several clinical trials on biologics for severe asthma. Depemokimab is an ultra-long-acting anti-IL-5 antibody with promising results in phase III trials as a twice-yearly biologic for T2-high asthma. Verekitug follows a similar dosing concept, targeting TSLP, but is still undergoing phase II trials. Itepekimab and astegolimab are two anti-IL-33 antibodies that could have a role in the future treatment of severe asthma. Tezepelumab is in a phase III clinical trial for CRSwNP. Besides new drugs, there is still a need for major research into biologics in severe asthma cases, namely with comparative studies, better biomarkers for predicting response, and the determination of optimal treatment duration.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pulmonology Department, Unidade Local de Saúde de Santo António, 4099-001 Porto, Portugal.
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal.
- Pulmonology Department, Unidade Local de Saúde de Matosinhos, 4464-513 Matosinhos, Portugal.
- Pulmonology Department, Unidade Local de Saúde de Alto Ave, 4835-044 Guimarães, Portugal.
- Pulmonology Department, Unidade Local de Saúde de Braga, 4710-243 Braga, Portugal.
- Pulmonology Department, Unidade Local de Saúde de Gaia e Espinho, 4434-502 Vila Nova de Gaia, Portugal.
ORCID-Profile: Nuno Faria, Maria Inês Costa, Francisco Machado, Liliana Ribeiro, Ricardo Lima
Zitieren
APA
Faria, N., Costa, M. I., Fernandes, A. L., Fernandes, A., Fernandes, B., Machado, D. C., Machado, F., Simão, L., Ribeiro, L., Ferreira, L., Boaventura, R., Lima, R., & Ferreira, J. (2025). Biologic Therapies for Severe Asthma: Current Insights and Future Directions. Journal of Clinical Medicine, 14(9), 3153. https://doi.org/10.3390/jcm14093153
Vancouver
Faria N, Costa MI, Fernandes AL, Fernandes A, Fernandes B, Machado DC, et al. Biologic Therapies for Severe Asthma: Current Insights and Future Directions. Journal of Clinical Medicine. 2025;14(9):3153. doi:10.3390/jcm14093153
BibTeX
@article{Faria2025,
author = {Faria, Nuno and Costa, Maria Inês and Fernandes, Ana Luísa and Fernandes, António and Fernandes, Beatriz and Machado, Daniela Cunha and Machado, Francisco and Simão, Laura and Ribeiro, Liliana and Ferreira, Lurdes and Boaventura, Rita and Lima, Ricardo and Ferreira, Jorge},
title = {Biologic Therapies for Severe Asthma: Current Insights and Future Directions},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {9},
pages = {3153},
doi = {10.3390/jcm14093153}
}
EUVIMED